{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5"}]}],"title":"Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"}]}],"title":"Not evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \\>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): \\>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \\>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. Not evaluable (NE): TL response is missing and there is no evidence of progression of NTLs and no new lesions. BOR is the best response (by investigator assessment) a patient has achieved where the order of best to worst is CR, PR, SD, PD, NE prior to or at progression and prior to further anti-cancer therapy.","groups":[{"description":"Phase II dose extension cohort in pre-treated EGFR T790M mutation positive patients in AZD9291 80mg tablet.","id":"OG000","title":"80mg AZD9291 Extension"}],"paramType":"NUMBER","populationDescription":"All patients in the 80mg AZD9291 extension part of the study (second line or later, EGFR T790M mutation positive by central testing) who received at least one dose of AZD9291 and had measurable disease (by investigator assessment) at baseline.","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 12 months (at the time of analysis)","title":"Best Objective Response (BOR) for 80mg AZD9291 Extension Population","type":"SECONDARY","unitOfMeasure":"% of participants"}